Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

BACKGROUND: In this study, our aim was to identify molecular aberrations predictive for response to everolimus, an mTOR inhibitor, regardless of tumor type. METHODS: To generate hypotheses about potential markers for sensitivity to mTOR inhibition, drug sensitivity and genomic profiles of 835 cell l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Weeber, Fleur, Cirkel, Geert A., Hoogstraat, Marlous, Bins, Sander, Gadellaa-van Hooijdonk, Christa G.M., Ooft, Salo, van Werkhoven, Erik, Willems, Stefan M., van Stralen, Marijn, Veldhuis, Wouter B., Besselink, Nicolle J.M., Horlings, Hugo M., Steeghs, Neeltje, de Jonge, Maja J., Langenberg, Marlies H.G., Wessels, Lodewyk F.A., Cuppen, Edwin P.J.G., Schellens, J.H., Sleijfer, Stefan, Lolkema, Martijn P., Voest, Emile E.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5589684/
https://ncbi.nlm.nih.gov/pubmed/28903445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16029
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados